A potent SARS-CoV-2 neutralizing human monoclonal antibody that reduces viral burden and disease severity in Syrian hamsters
The emergence of COVID-19 has led to a pandemic that has caused millions of cases of disease, variable morbidity and hundreds of thousands of deaths. Currently, only remdesivir and dexamethasone have demonstrated limited efficacy, only slightly reducing disease burden, thus novel approaches for clinical management of COVID-19 are needed. We identified a panel of human monoclonal antibody clones from a yeast display library with specificity to the SARS-CoV-2 spike protein receptor binding domain that neutralized the virus in vitro . Administration of the lead antibody clone to Syrian hamsters challenged with SARS-CoV-2 significantly reduced viral load and histopathology score in the lungs. Moreover, the antibody interrupted monocyte infiltration into the lungs, which may have contributed to the reduction of disease severity by limiting immunopathological exacerbation. The use of this antibody could provide an important therapy for treatment of COVID-19 patients.
| Errataetall: |
UpdateIn: Front Immunol. 2020 Dec 18;11:614256. - PMID 33391285 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2020 |
|---|---|
| Enthalten in: |
bioRxiv : the preprint server for biology - (2020) vom: 28. Sept. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fagre, Anna C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 08.01.2021 published: Electronic UpdateIn: Front Immunol. 2020 Dec 18;11:614256. - PMID 33391285 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2020.09.25.313601 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315951435 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315951435 | ||
| 003 | DE-627 | ||
| 005 | 20231225160026.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.09.25.313601 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1053.xml |
| 035 | |a (DE-627)NLM315951435 | ||
| 035 | |a (NLM)33024962 | ||
| 035 | |a (PII)2020.09.25.313601 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fagre, Anna C |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A potent SARS-CoV-2 neutralizing human monoclonal antibody that reduces viral burden and disease severity in Syrian hamsters |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.01.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: Front Immunol. 2020 Dec 18;11:614256. - PMID 33391285 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The emergence of COVID-19 has led to a pandemic that has caused millions of cases of disease, variable morbidity and hundreds of thousands of deaths. Currently, only remdesivir and dexamethasone have demonstrated limited efficacy, only slightly reducing disease burden, thus novel approaches for clinical management of COVID-19 are needed. We identified a panel of human monoclonal antibody clones from a yeast display library with specificity to the SARS-CoV-2 spike protein receptor binding domain that neutralized the virus in vitro . Administration of the lead antibody clone to Syrian hamsters challenged with SARS-CoV-2 significantly reduced viral load and histopathology score in the lungs. Moreover, the antibody interrupted monocyte infiltration into the lungs, which may have contributed to the reduction of disease severity by limiting immunopathological exacerbation. The use of this antibody could provide an important therapy for treatment of COVID-19 patients | ||
| 650 | 4 | |a Preprint | |
| 700 | 1 | |a Manhard, John |e verfasserin |4 aut | |
| 700 | 1 | |a Adams, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Eckley, Miles |e verfasserin |4 aut | |
| 700 | 1 | |a Zhan, Shijun |e verfasserin |4 aut | |
| 700 | 1 | |a Lewis, Juliette |e verfasserin |4 aut | |
| 700 | 1 | |a Rocha, Savannah M |e verfasserin |4 aut | |
| 700 | 1 | |a Woods, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Kuo, Karina |e verfasserin |4 aut | |
| 700 | 1 | |a Liao, Wuxiang |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Corper, Adam |e verfasserin |4 aut | |
| 700 | 1 | |a Challa, Dilip |e verfasserin |4 aut | |
| 700 | 1 | |a Mount, Emily |e verfasserin |4 aut | |
| 700 | 1 | |a Tumanut, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Tjalkens, Ronald B |e verfasserin |4 aut | |
| 700 | 1 | |a Aboelleil, Tawfik |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Xiaomin |e verfasserin |4 aut | |
| 700 | 1 | |a Schountz, Tony |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv : the preprint server for biology |d 2020 |g (2020) vom: 28. Sept. |w (DE-627)NLM31090014X |7 nnns |
| 773 | 1 | 8 | |g year:2020 |g day:28 |g month:09 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.09.25.313601 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2020 |b 28 |c 09 | ||